RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07005583, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Female breast cancer patients aged ≥18 and ≤75 years, with histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer (TNBC) as defined by the latest ASCO/CAP guidelines (based on the most recent biopsy or other pathological specimens).

    Inclusion criterion 2

  3. Have received at least 1 but no more than 2 prior lines of anti-tumor therapy ( Disease progression during or within 12 months after completing neoadjuvant/adjuvant therapy counts as one line of therapy;Must have received taxane-based therapy at any stage;A maximum of 1 prior antibody-drug conjugate (ADC) therapy is allowed.)

    Inclusion criterion 3

  4. Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4) or PARP inhibitors (e.g., olaparib, niraparib).

    Exclusion criterion 1

    Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.

    Exclusion criterion 4

    Major surgery within 4 weeks prior to treatment or anticipated during the study (excluding diagnostic procedures).

    Exclusion criterion 14

    Prior radiotherapy (except palliative bone radiation), chemotherapy, or surgery (excluding biopsy) within 4 weeks before treatment initiation; <4 weeks since last antibody therapy; <5 half-lives since last targeted therapy (including investigational agents); or unresolved toxicities (>CTCAE grade 1, except alopecia).

    Exclusion criterion 16

  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

    Inclusion criterion 7

  6. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.

    Exclusion criterion 17

  7. Have at least one measurable lesion according to RECIST 1.1 criteria (assessed by CT or MRI). Bone-only lesions are considered non-measurable and do not qualify for enrollment.

    Inclusion criterion 6

  8. History of other malignancies (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless disease-free for ≥3 years.

    Exclusion criterion 7

    Immunodeficiency (e.g., HIV); HBsAg-positive with HBV DNA ≥2000 IU/mL; or HCV antibody-positive.

    Exclusion criterion 18

  9. Planning pregnancy, pregnancy, or suckling period;

    Exclusion criterion 21

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07005583, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.
  • Female breast cancer patients aged ≥18 and ≤75 years, with histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer (TNBC) as defined by the latest ASCO/CAP guidelines (based on the most recent biopsy or other pathological specimens).
  • Have received at least 1 but no more than 2 prior lines of anti-tumor therapy ( Disease progression during or within 12 months after completing neoadjuvant/adjuvant therapy counts as one line of therapy;Must have received taxane-based therapy at any stage;A maximum of 1 prior antibody-drug conjugate (ADC) therapy is allowed.)
  • Documented homologous recombination repair deficiency (HRD) (BRCA1/2 mutation and/or HRD-positive status.
  • Any PD-L1 expression status (no restriction).
  • Have at least one measurable lesion according to RECIST 1.1 criteria (assessed by CT or MRI). Bone-only lesions are considered non-measurable and do not qualify for enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Availability of tumor tissue samples for biomarker testing.
  • Ability to swallow tablets normally.
  • Expected survival ≥3 months.
  • Presence of adequate bone marrow and organ function.

Exclusion Criteria:

  • Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4) or PARP inhibitors (e.g., olaparib, niraparib).
  • Current use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment.
  • History of severe allergic reactions to monoclonal antibodies.
  • Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.
  • Known history or evidence of interstitial lung disease or active non-infectious pneumonitis.
  • History of CNS metastases or current CNS metastases. Baseline imaging to confirm absence of brain metastases is not mandatory. Patients with unknown CNS status but clinical signs suggestive of CNS involvement are eligible if CNS metastases are ruled out by CT/MRI.
  • History of other malignancies (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless disease-free for ≥3 years.
  • Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) despite antihypertensive therapy. History of hypertensive crisis or hypertensive encephalopathy.
  • History of unstable angina, myocardial infarction, chronic heart failure (LVEF <50%), or clinically significant arrhythmias requiring treatment (except stable atrial fibrillation) within 6 months prior to treatment.
  • Current therapeutic anticoagulation or thrombolysis (prophylactic low-dose aspirin/LMWH permitted).
  • Clinically significant effusions (pleural, peritoneal, or pericardial) requiring drainage, unless stabilized post-drainage per investigator assessment.
  • Arterial/venous thromboembolic events (e.g., CVA, TIA, DVT, PE) within 6 months prior to enrollment.
  • Major vascular disease (e.g., aortic aneurysm requiring repair or recent peripheral arterial thrombosis) within 6 months.
  • Major surgery within 4 weeks prior to treatment or anticipated during the study (excluding diagnostic procedures).
  • Urine protein ≥++ on dipstick with confirmed 24-hour urine protein >1.0 g.
  • Prior radiotherapy (except palliative bone radiation), chemotherapy, or surgery (excluding biopsy) within 4 weeks before treatment initiation; <4 weeks since last antibody therapy; <5 half-lives since last targeted therapy (including investigational agents); or unresolved toxicities (>CTCAE grade 1, except alopecia).
  • Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.
  • Immunodeficiency (e.g., HIV); HBsAg-positive with HBV DNA ≥2000 IU/mL; or HCV antibody-positive.
  • Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma resolved without intervention, or stable hypothyroidism on hormone replacement.
  • Live vaccination within 4 weeks prior to treatment or planned during the study.
  • Planning pregnancy, pregnancy, or suckling period;
  • The investigator judged that the patients are not suitable for participating in this trial.

Quoted from ClinicalTrials.gov, NCT07005583, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07005583, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07005583